Non-Small Cell Lung Cancer
For clinical stage 1 non-small-cell lung cancer, 21.7% of patients upstaged after 1 week and 31.5% after 8 weeks.
Nivolumab plus ipilimumab linked to better survival in NSCLC with high tumor mutational burden.
Dacomitinib is a pan-human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
Many octogenarians and nonagenarians with non-small cell lung cancer do not receive cancer-directed care.
Adjuvant chemotherapy administered prior to, rather than concurrently with, radiotherapy improves survival outcomes among patients with NSCLC.
Survival is better with lobectomy than SBRT in patients with NSCLC.
Treatment with osimertinib is associated with longer progression-free survival in patients with previously untreated EGFR mutation-positive advanced non-small-cell lung cancer.
Between 2000 and 2010, researchers identified a decline in the number of patients with stage I NSCLC who remained untreated.
Results of two phase 3 studies found that nivolumab provided superior overall survival vs docetaxel in people with non-small cell lung cancer.
Patients with NSCLC experienced improvements in both function and quality of life with yoga therapy.
Study results stress the importance of a multiethnic support system for patients needing to overcome communication barriers.
First generation EGFR tyrosine kinase inhibitors should be used in combination with chemotherapy if a patient has progressive EGFR mutation-positive non-small cell lung cancer.
Dacomitinib improved progression-free survival in patients with non-small cell lung cancer.
Fewer than 30% of patients undergoing durvalumab therapy experienced either grade 3 or 4 adverse events.
Recommendations to include CT scans as standard follow-up procedure is based on poor evidence.
Data from 5 phase 2/3 studies demonstrate improved weight and body mass in patients with NSCLC receiving anamorelin.
A phase 3 trial examined the efficacy of chemoimunnotherapy vs chemotherapy alone in postsurgical patients with non-small cell lung cancer.
Priority review for alectinib was granted based on evidence from the phase 3 ALEX and J-ALEX clinical trials.
Durvalumab can be used to treat patients with locally advanced, unrescetable NSCLC, who do not relapse after platinum-based chemoradiation.
Valuable information regarding patients' life expectancy can be collected through neutrophil-lymphocyte ratio biomarkers.
Researchers considered the response rate "encouraging" and comparable to cisplatin-based neoadjuvant therapy outcomes.
Findings in patients with previously untreated disease with PD-L1 expression level of 5%.
Increased radiation therapy based on midtreatment residual tumor FDG-PET may improve local control among patients with advanced NSCLC.
Adjuvant gefitnib increases disease-free survival for patients with stage II to III non-small lung cancer.
Data can be used to target the development of new drugs for treating squamous cell carcinomas.
The added combination of selumetinib with docetaxel did not improve progression-free survival among patients previously treated for advanced NSCLC.
Developed in Cuba, the TG4010 and CIMAvax-EGF vaccines are undergoing clinical study in the US.
Two new medications may improve survival for patients with specific types of advanced non-small-cell lung cancer.
Participants in the phase 3 PACIFIC trial randomly received sequential treatment with either durvalumab or placebo.
Alectinib, a selective ALK inhibitor, was found to have an objective response rate of 92% among patients with ALK-positive NSCLC.